What Grey Wolf Therapeutics say about themselves
“Novel antigen modulation technology that controls T cells to guide the immune system”
“Novel antigen modulation technology that controls T cells to guide the immune system”
Officer details are public data from the Companies House register.
People and entities with significant control, from the Companies House PSC register
Figures from 2024 accounts. Newer accounts, made up to 31 December 2025, are filed but not read yet. See them on Companies House
| 2024 | 2023 | 2022 | 2020 | |
|---|---|---|---|---|
| Fixed Assets | £62,879 | £57,116 | £77,508 | |
| Current Assets | £28,838,439 | £15,638,192 | £10,982,048 | £9,968,535 |
| Cash | £20,417,134 | £9,031,259 | £9,568,847 | £862,006 |
| Creditors (< 1 year) | £2,613,206 | £2,329,021 | £928,661 | £719,836 |
| Net Current Assets | £26,225,233 | £13,309,171 | £10,053,387 | £9,248,699 |
| Net Assets | £26,288,112 | £13,366,287 | £10,130,895 | £9,325,031 |
| Shareholder Funds | £26,288,112 | £13,366,287 | £10,130,895 | £9,325,031 |
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 23 October 2026 | Statement of capital following an allotment of shares | |||
| 22 October 2026 | Termination of appointment of a director | |||
| 20 October 2026 | Confirmation statement with updates | 30 September 2026 | ||
| 14 September 2026 | Amended accounts for a small company | 31 December 2025 | ||
| 26 August 2026 | Accounts for a small company | 31 December 2025 |
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →